JPH0413324B2 - - Google Patents

Info

Publication number
JPH0413324B2
JPH0413324B2 JP55501805A JP50180580A JPH0413324B2 JP H0413324 B2 JPH0413324 B2 JP H0413324B2 JP 55501805 A JP55501805 A JP 55501805A JP 50180580 A JP50180580 A JP 50180580A JP H0413324 B2 JPH0413324 B2 JP H0413324B2
Authority
JP
Japan
Prior art keywords
conjugate
binding
insulin
glucose
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP55501805A
Other languages
English (en)
Japanese (ja)
Other versions
JPS56500965A (enExample
Inventor
Mikaeru Buraunrii
Ansonii Serami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JPS56500965A publication Critical patent/JPS56500965A/ja
Publication of JPH0413324B2 publication Critical patent/JPH0413324B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
JP55501805A 1979-07-31 1980-07-30 Expired - Lifetime JPH0413324B2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/062,484 US4348387A (en) 1979-07-31 1979-07-31 Method and system for the controlled release of biologically active substances to a body fluid

Publications (2)

Publication Number Publication Date
JPS56500965A JPS56500965A (enExample) 1981-07-16
JPH0413324B2 true JPH0413324B2 (enExample) 1992-03-09

Family

ID=22042805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55501805A Expired - Lifetime JPH0413324B2 (enExample) 1979-07-31 1980-07-30

Country Status (7)

Country Link
US (1) US4348387A (enExample)
EP (1) EP0032927B1 (enExample)
JP (1) JPH0413324B2 (enExample)
BR (1) BR8008775A (enExample)
CA (1) CA1168983A (enExample)
DE (1) DE3069598D1 (enExample)
WO (1) WO1981000354A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
AU733391B3 (en) * 1982-04-26 2001-05-10 American National Can Company Polymeric and film structure for use in heat shrinkable bags
EP0119650A3 (en) * 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1329761C (en) * 1988-07-25 1994-05-24 Vettai S. Ananthanarayanan Design of peptide hormones, chemotactic peptides and drug compounds
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2003301064A1 (en) * 2002-12-17 2004-07-14 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
WO2007047922A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Polymer-drug conjugates
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
JP2012516342A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 結晶性インスリン複合体
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
EP2408470A4 (en) * 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICINAL LIGANDEN CONJUGATES, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREOF
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3600381A4 (en) 2017-03-23 2021-06-16 Merck Sharp & Dohme Corp. GLUCOSE-ACTIVE INSULIN WITH A THREE-VALUE SUGAR CLUSTER FOR THE TREATMENT OF DIABETES
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
EP3586876A1 (en) * 2018-06-21 2020-01-01 Gubra ApS Glucose-sensitive peptide hormones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
DE2054446A1 (de) * 1970-11-05 1972-05-10 Henning, George Ernest von, 6800 Mannheim Biologische Reaktionskammer
US3857393A (en) * 1971-04-22 1974-12-31 Bio Response Inc Apparatus for use in the augmentation of the production of antibodies in animals and humans and the collection thereof
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
CA1040271A (en) * 1975-01-22 1978-10-10 Anthony M. Albisser Artificial beta cell

Also Published As

Publication number Publication date
JPS56500965A (enExample) 1981-07-16
EP0032927A4 (en) 1982-05-10
WO1981000354A1 (en) 1981-02-19
DE3069598D1 (en) 1984-12-13
CA1168983A (en) 1984-06-12
EP0032927A1 (en) 1981-08-05
BR8008775A (pt) 1981-05-26
EP0032927B1 (en) 1984-11-07
US4348387A (en) 1982-09-07

Similar Documents

Publication Publication Date Title
US4348387A (en) Method and system for the controlled release of biologically active substances to a body fluid
US4469681A (en) Method and system for the controlled release of biologically active substances to a body fluid
Farraj et al. Nasal administration of insulin using bioadhesive microspheres as a delivery system
US6342225B1 (en) Pharmaceutical active conjugates
JP2547054B2 (ja) キメラペプチド及びそれを含む組成物
Bratusch-Marrain et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
LEAHY et al. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion
Jeong et al. Self-regulating insulin delivery systems I. Synthesis and characterization of glycosylated insulin
US6063761A (en) Hepatoselective pharmaceutical actives
US4959358A (en) Drug administration
US7138486B2 (en) Insulinotropic hormone derivatives and uses thereof
Bhathena et al. Decreased glucagon receptors in diabetic rat hepatocytes: evidence for regulation of glucagon receptors by hyperglucagonemia
JPH0196137A (ja) 真性糖尿病の治療
ZA200306332B (en) Methods of treating diabetes mellitus
Leicht et al. Inhibition of Releasing-Hormone-lnduced Secretion of TSH and LH by Calcitonin
KR101058467B1 (ko) 부신피질 자극 호르몬 유사체 및 관련 방법
EP0119650A2 (en) Galactosyl-insulin conjugates useful in treating diabetics
Zor et al. Implication of microtubules and microfilaments in the response of the ovarian adenylate cyclase-cyclic AMP system to gonadotropins and prostaglandin E2
CURRY et al. Dynamics of insulin release by perfused rat pancreases: effects of hypophysectomy, growth hormone, adrenocorticotropic hormone and hydrocortisone
Gershonov et al. New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin.
Bremner et al. Pituitary-thyroid responses to 4-hour constant infusions of thyrotropin releasing hormone in man
Kim et al. Self regulating insulin delivery system—a chemical approach
Nolin The prolactin incorporation cycle of the milk secretory cell. An integral component of the prolactin response cycle.
AU6129080A (en) Method and system for the controlled release of biologically active substances to a body fluid
Martin et al. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep